The severe side effects of glucocorticoids prevent long term management of hearing loss. Alternative steroid treatments that minimize or eliminate these effects would significantly benefit therapeutic control of hearing disorders. A steroid treatment study of autoimmune mouse hearing loss was conducted to determine the efficacy of combining aldosterone and prednisolone at low doses. An assessment also was made of low dose fludrocortisone, a synthetic mineralocorticoid that also has a slight glucocorticoid effect. MRL/MpJ-Fas lpr mice were tested for baseline ABR thresholds at 3 months of age and then treated with aldosterone (3.0 μg/kg) or prednisolone (1.0 mg/kg) to determine the lowest effective dose of each. Other mice were given the two steroids in combination at doses of Pred 0.5 mg+ Aldo 1.5 μg; Pred 1.0 mg+ Aldo 3.0 μg; or Pred 1.5 mg+ Aldo 5.0 μg. Mice were retested with ABR at 1 and 2 months to determine the efficacy of the different steroid treatments in controlling hearing loss. Another series of mice were given the synthetic mineralocorticoid fludrocortisone at low (2.8 μg/kg) or high (10 μg/kg) doses and retested at monthly intervals for 3 months. Autoimmune mouse hearing loss developed in untreated controls. This threshold elevation was not prevented by prednisolone at 1 mg/kg or by aldosterone at 3 μg/kg when each was given alone. However, the two steroids combined at these doses effectively controlled hearing loss. The fludrocortisone treatments also were effective at low doses in preventing or reversing the autoimmune mouse hearing loss. This efficacy of combined steroids at low doses suggests the potential for reducing the side effects of glucocorticoids in the therapeutic control of hearing disorders.
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Introduction
Because hearing loss is often suspected to result from immunemediated or inflammatory processes (Dornhoffer et al., 1997) , glucocorticoids (prednisone, prednisolone, and dexamethasone) are frequently used to treat such hearing disorders as sudden or rapidly progressive hearing loss (Alexiou et al., 2001; Rauch, 2004; Aoki et al., 2006 ), Meniere's disease (Barrs, 2004) , and autoimmune inner ear disease (AIED) (Loveman et al., 2004; Niparko et al., 2005) . However, in spite of the glucocorticoids' effectiveness, their severe side effects prevent long term management of such inner ear dysfunction (Nadel, 1996; Sismanis et al., 1997; Trune et al., 2007) . Alternative steroid treatments that minimize or eliminate these side effects would have significant benefit in the therapeutic control of hearing disorders.
This laboratory has been studying the steroid control of hearing loss in the MRL/MpJ-Fas lpr autoimmune mouse model to better understand these steroid-responsive mechanisms in the ear. Autoimmune mouse hearing loss progresses with systemic disease development, pathology is limited to the stria vascularis, and treatment with the mineralocorticoid aldosterone is as effective as prednisolone in reversing or preventing hearing loss (Trune and Kempton, 2001 ). The mineralocorticoid receptor-mediated function (ion homeostasis) of glucocorticoids was determined to be as important for hearing control as their glucocorticoid receptor-mediated functions (anti-inflammation and immunosuppression) (Trune et al., 2006; Trune and Kempton, 2009 ). The autoimmune mouse loses strial endothelial cell tight junction integrity due to immune complexes (Trune, 1997), which causes a drop in the endocochlear potential and hearing loss (Lin and Trune, 1997; Ruckenstein et al., 1999) . Thus, restoration of strial ion homeostatic processes by mineralocorticoid receptor-mediated processes appears critical for hearing recovery, in spite of the initiating cause being systemic autoimmune disease. This parallels current hypotheses that some human AIED is due to circulating inflammatory factors (inflammatory cells, autoantibodies) that disrupt cochlear vasculature (Harris and Ryan, 1995; Barna and Hughes, 1997; Garcia-Berrocal and RamirezCamacho, 2002; Mathews and Kumar, 2003; Yehudai et al., 2006) . Given this relevance of the mineralocorticoid function of glucocorticoids for recovery of AIED, it is possible that both mineralocorticoid and glucocorticoid steroids could be employed in combination. If their effects are complementary or additive, combining them at lower doses may still provide therapeutic control of hearing loss while reducing glucocorticoid side effects. Therefore, the present study was conducted to determine if the mineralocorticoid aldosterone and the glucocorticoid prednisolone could be combined at low doses to effectively treat hearing loss in the autoimmune mouse model. If reduced levels of each are needed when combined, it would provide important preliminary Journal of Neuroimmunology 229 (2010) 140-145 
